Head to head
Tandem Diabetes Care vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: TNDM · ABT
TNDM
Tandem Diabetes Care
16.11+2.78%
1-year price shape — +9% over the period
Quant Rating D · 45/100
vs
ABT
Abbott Laboratories
99.60+1.13%
1-year price shape — -24% over the period
Quant Rating D · 16/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| TNDM | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Medical Devices |
| Last price | 16.11 | 99.60 |
| Change today | +2.78% | +1.13% |
| 1-year return | +8.7% | -23.6% |
| Market cap | $1.12B | $172.35B |
| 52-week range | 12.26 – 29.65 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | -17.90 | 32.23 |
| P/E percentile, own 5-yr range | 30th | 62nd |
| P/B | 8.60 | 3.37 |
| Dividend yield | 0.00% | 2.45% |
| Profitability & growth | ||
| EPS (TTM) | -3.04 | 3.72 |
| Net profit (TTM) | $-211.52M | $6.44B |
| Revenue (TTM) | $1.04B | $46.59B |
| Revenue growth (YoY) | +5.8% | +13.0% |
| Gross margin | 56.0% | 56.6% |
| Operating margin | -4.4% | 15.8% |
| Net margin | -6.1% | 11.6% |
| Free cash flow (TTM) | $-61.74M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 116.0% | 81.1% |
| Insider activity (12mo) | 36 buy / 14 sell | 36 buy / 12 sell |
| Short interest (% of float) | 19.2% | 0.8% |
| Analyst consensus | 58% buy / 42% hold (12) | 100% buy (14) |
| Analyst price target | $28 (+75%) | $126 (+26%) |
| StockVane view | ||
| StockVane Quant Rating | D (45) | D (16) |
| Company | ||
| Employees | 2,500 | 115,000 |
| Founded | 2006 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.